Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15490019 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL15490021 | 0.86 | SMN1; SMN2 (0.52) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL30333932 | 0.84 | SMN1; SMN2 (0.43) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL12414849 | 0.84 | SMN1; SMN2 (0.46) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL5744444 | 0.84 | SMN1; SMN2 (0.46) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL12414847 | 0.84 | SMN1; SMN2 (0.46) | DPP4DPP8DPP9SMN1; SMN2POLB | |
| SCHEMBL24614018 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL19431618 | 0.81 | SMN1; SMN2 (0.52) | DPP4DPP8SMN1; SMN2POLBNPSR1 | |
| SCHEMBL18731194 | 0.81 | SMN1; SMN2 (0.52) | DPP4DPP8SMN1; SMN2POLBNPSR1 | |
| SCHEMBL12304221 | 0.81 | DPP4 (0.51) | DPP4SMN1; SMN2POLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | DPP4 2723/4885DPP8 2556/4885DPP9 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.